This retrospective study describes the outcome in 53 patients who had immunosuppressive treatment changed from cyclosporine (CSP) to tacrolimus for resistant acute GVHD (n = 23), hemolytic uremic syndrome (HUS) (n = 13) or CSP-associated neurotoxicity (n = 17). Tacrolimus was administered at doses of 0.03 mg/kg/day intravenously or 0.12 mg/kg/day orally in divided doses, as tolerated. Median time of conversion to tacrolimus after transplant was day 47. Nineteen patients had treatment changed to tacrolimus for resistant acute GVHD grades III or IV, with the median day of conversion being day 49 after transplant. Two of 20 evaluable patients had a complete resolution of GVHD after changing treatment to tacrolimus, with 18 showing no improvement. Eleven evaluable patients had therapy changed to tacrolimus for CSP-associated neurotoxicity at a median of 36 days after transplant. Eight patients had resolution of neurotoxicity and three had partial improvement. Eleven evaluable patients had therapy changed to tacrolimus for HUS at a median of 46 days after transplant. One patient had complete resolution of HUS and 10 showed no response. Side-effects related to tacrolimus included renal toxicity (34%), neurotoxicity (15%) and HUS (9%). Nine (17%) patients remain alive, including six patients who had therapy changed to tacrolimus for CSP-associated neurotoxicity. While often successful for dealing with neurotoxicity, only a rare patient improved after therapy was changed from CSP to tacrolimus for HUS or resistant acute GVHD. Bone Marrow Transplantation (2000) 26, 985-991.
Graft-versus-host disease (GVHD) remains a significant obstacle to successful outcome after hematopoietic stem cell transplantation, particularly in recipients of unrelated and HLA-mismatched grafts. [1] [2] [3] [4] [5] Treatment for acute GVHD includes high-dose glucocorticoids and antithymocyte globulin (ATG), although less than half of these patients will show a durable sustained response to these therapies. 6, 7 Use of cyclosporine (CSP) for the prevention of acute GVHD has been associated with considerable toxicity, most often nephrotoxicity and neurologic complications. 8 The macrolide tacrolimus, like CSP, inhibits T cell activation by blocking the phosphatase activity of calcineurin. 9 Tacrolimus is effective in preventing allograft rejection following liver transplantation 10, 11 and as rescue therapy in treating graft rejection following renal, liver and pancreatic transplantation utilizing CSP-based immunosuppression. [12] [13] [14] [15] [16] In these settings, therapy has been successfully converted from CSP to tacrolimus when CSP toxicity occurred. [17] [18] [19] Clinical studies in marrow transplantation have shown that tacrolimus can prevent acute GVHD following matched sibling and unrelated donor transplants. [20] [21] [22] [23] [24] A number of small studies have also reported success with tacrolimus as salvage therapy for steroid-resistant acute GVHD. [25] [26] [27] [28] Based on these reports, we have reviewed our experience in converting therapy from CSP to tacrolimus because of CSP toxicity or following development of refractory acute GVHD.
Patients and methods

Patients
A retrospective analysis was conducted of results in 53 sequential patients who underwent allogeneic marrow or peripheral blood stem cell transplantation at the Fred Hutchinson Cancer Research Center (FHCRC) between July 1994 and October 1997 and had therapy changed from CSP to tacrolimus-based immunosuppression within 100 days of transplant for CSP toxicity or refractory acute GVHD. In order to categorize response in groups of patients experiencing CSP toxicity, analysis was restricted to patients who had therapy changed to tacrolimus due to hemolytic uremic syndrome (HUS) or neurologic dysfunction, where CSP was thought to be the primary cause of toxicity. Two additional patients, not included in this analysis, had therapy changed from CSP to tacrolimus due to hyperbilirubinemia unrelated to HUS and following the development of a pericardial effusion thought possibly to be due to CSP. Patients were considered not evaluable in cases where it was determined that the etiology of the toxicity was uncertain due to the presence of other confounding factors. Patients were analyzed based on the reason for conversion to tacrolimus. All patients had previously given informed consent for treatment protocols approved by the FHCRC Institutional Review Board.
Assessment of GVHD and cyclosporine toxicity before converting to tacrolimus
The assessment and grading of acute and chronic GVHD has been described. 29, 30 The acute GVHD grading scale was modified slightly to allow for the grading of biopsy-proven intestinal acute GVHD limited to nausea, vomiting or anorexia (stage 1). Acute GVHD at the time of conversion to tacrolimus was graded with no consideration as to whether other complications existed that may have contributed to organ dysfunction. Patients were evaluable for chronic GVHD if they survived 80 days after transplant without relapse of the underlying disease.
The diagnosis of HUS was determined by the presence of a constellation of clinical signs and laboratory values. In general, an elevated serum lactate dehydrogenase (LDH), decreased haptoglobin in association with a decreased hematocrit, decreased platelet count and the presence of schistocytes on peripheral smear, with or without renal dysfunction, was considered evidence of HUS.
Cyclosporine-associated neurologic dysfunction was determined clinically and by diagnostic testing, including computerized tomography (CT), magnetic resonance imaging (MRI), electroencephalogram (EEG) and examination of cerebral spinal fluid (CSF). Efforts were made to rule out or eliminate other causative factors or agents (ie medications) that may have contributed to neurologic dysfunction prior to discontinuing CSP and starting tacrolimus.
GVHD prophylaxis
Regimens for GVHD prophylaxis are described in Table 1 . Cyclosporine was administered at 3 mg/kg/day as an intravenous infusion given in two divided doses or as a continuous infusion. The dose of oral CSP was 12 mg/kg/day given in divided doses. Prior to January 1996, CSP levels were targeted at 150-600 ng/ml utilizing a TDX plasma polyclonal assay. Thereafter, levels were targeted at 300-1200 ng/ml utilizing a TDX whole blood polyclonal assay.
Treatment
In all patients, CSP was discontinued prior to starting tacrolimus. The initial dose of tacrolimus was based on the patient's renal and liver function and previous CSP dose. The full dose of tacrolimus was 0.03 mg/kg/day intravenously as a continuous infusion or 0.12 mg/kg/day orally in divided doses. Efforts were made to maintain therapeutic levels of tacrolimus (10-30 ng/ml) utilizing an IMX whole blood assay. Continuation of concurrent immunosuppressants and initiation of additional immunosuppression for management of acute GVHD was determined by the attending physician based on clinical response.
Measurements of response
Response of acute GVHD to tacrolimus was based on methods previously described by Martin et al, 31 with some modifications. Patients were evaluated 6 weeks after conversion to tacrolimus or at the time of death or discontinuation of tacrolimus, if this occurred earlier, with consideration given to organ dysfunction (skin, gut and liver) which may have been caused by factors other than GVHD. Patients had to be treated for a minimum of 3 days with tacrolimus to be considered evaluable. Patients who received additional immunosuppression for GVHD after starting tacrolimus were evaluated for organ response up to the time additional immunosuppressants were begun. The effect of altered renal function or serum bilirubin was not a factor in measuring response in liver disease.
Overall, complete response (CR) was defined as the absence of clinical symptoms referable to acute GVHD in all organs. Partial response (PR) was defined as the improvement of clinical symptoms in at least one organ without progression in other organs. 31 No response (NR) was defined as failure to meet the minimum criteria for improvement in any affected organ or the requirement for additional therapy to control GVHD after starting tacrolimus.
Resolution of HUS was defined as (1) a decrease of у50% in serum LDH baseline value or a level р250 /l, (2) an increase in haptoglobin to у20 mg/dl, and (3) a clearance of schistocytes on peripheral smear. No response was failure to meet the minimum criteria for response, discontinuation of tacrolimus due to HUS or the requirement for plasmapheresis after starting tacrolimus. Patients had to be treated for a minimum of 3 days to be considered evaluable.
Resolution of neurologic toxicity was based solely on improvement in clinical symptoms. Complete response was defined as resolution with no recurrence of the original neurologic dysfunction thought due to CSP. Partial response was defined as improvement in neurologic dysfunction and continued use of tacrolimus therapy in the presence of residual neurologic symptoms or recurrence of symptoms. No response was no change in neurologic dysfunction or discontinuation of tacrolimus due to neurotoxicity. Patients had to be treated with tacrolimus for a minimum of 3 days to be considered evaluable.
Tacrolimus toxicity
Nephrotoxicity was defined as a doubling of the baseline serum creatinine or a serum creatinine greater than 2 mg/dl. The serum creatinine at the time of conversion to tacrolimus was considered as baseline. Other toxicities, such as HUS and neurotoxicity, were defined as previously described.
Results
Patient characteristics
Fifty-three patients transplanted at FHCRC between July 1994 and October 1997 had therapy changed from CSP to tacrolimus-based immunosuppression within 100 days after transplant. Patient characteristics are summarized in Table  1 . The reasons for conversion to tacrolimus were refractory acute GVHD (n = 23), CSP-associated neurotoxicity (n = 17) and HUS (n = 13). The median day after transplant for conversion to tacrolimus for all patients was day 47.
GVHD characteristics and response to treatment
Twenty-three patients (43%) had therapy changed from CSP to tacrolimus due to refractory acute GVHD (Table  2) . Initial therapy for acute GVHD prior to conversion to tacrolimus was with corticosteroids, with the exception of three patients who received cyclosporine. Other agents used to treat GVHD included ATG, mycophenolate mofetil, rapamycin, beclomethasone and psoralen with ultraviolet A light (PUVA). Prior to starting tacrolimus, 12 patients had Bone Marrow Transplantation Table 2 Patients with refractory acute GVHD and response to tacrolimus (n = 23) received two different therapies for treatment of GVHD and five had received three or more therapies, making tacrolimus tertiary treatment for the majority of patients. The median time to converting to tacrolimus was day 49 after transplantation, with 4 patients having grade II GVHD and 19 having grades III-IV GVHD at the time of conversion. Median time of onset of GVHD was day 12 after transplantation. The median number of days between the onset of acute GVHD and the start of tacrolimus was 37. Eighteen patients had GVHD affecting at least two organs, with intestinal involvement in 20 patients and liver involvement in 17 patients. Many of these patients were severely ill, and the conversion to tacrolimus was a final effort to control refractory GVHD. Complete responses to tacrolimus were seen in two patients, and 18 patients showed no response. Three patients were not evaluable for response: two patients died and received less than 3 days of therapy and one patient started ATG on the day of conversion to tacrolimus. Nine patients who did not respond received additional immunosuppression after starting tacrolimus. Neither of the two responders required additional immunosuppression for acute GVHD. Only two patients in this group are surviving.
Bone Marrow Transplantation
Neurologic toxicity and response to conversion
Seventeen patients (32%) had therapy changed to tacrolimus because of CSP-associated neurotoxicity (Table 3) . The median time of conversion was day 36 after transplantation (range 14-94 days). Ten of 11 evaluable patients had CSP levels within or below the target range at the time of the neurologic event. Eight patients showed a complete response after therapy was converted to tacrolimus. Three patients had partial responses, including two patients who had recurring tremor after initial improvement and one Table 3 Patients with CSP neurotoxicity and response to tacrolimus (n = 17) (1) TDX plasma polyclonal assay, target range 150-600 ng/ml; (2) TDX whole blood polyclonal assay, target range 300-1200 ng/ml. patient with cortical blindness who had recurring scotomata after therapy was changed to tacrolimus. Six patients in this group remain alive. Six patients could not be evaluated for response. Two patients (UPNs 10328, 10767) had recurrence of pretransplant chemotherapy-induced neurologic toxicity, and three patients had confounding concomitant illnesses, including a viral infection (UPN 12424), CNS emboli (UPN 12289), and metabolic abnormalities with significant hypothermia (UPN 10601). One patient (UPN 11186) had mental status changes most likely attributable to corticosteroids.
Hemolytic uremic syndrome and response to conversion
Thirteen patients (25%) developed HUS presumed due to CSP and had therapy changed to tacrolimus. The median time of conversion was day 46 after transplantation (range 13-86 days). The median day of onset of HUS was day 39 after transplantation (range 12-64 days). All patients presented with an elevated LDH (median, 1079 /l), 11 showed schistocytes on peripheral smear and 12 had a low haptoglobin. Most patients had some degree of hepatic or renal insufficiency. There was no change in eight patients after the conversion to tacrolimus and one patient had a complete response. In two cases, HUS recurred after the patients had initially shown a good response to tacrolimus. Two patients were not evaluable, one because CSP was reinstituted after two doses of tacrolimus due to a flare of GVHD and the other due to lack of follow-up laboratory parameters necessary to determine response. Three patients required plasma apheresis, two after starting tacrolimus. Only one patient in this group remains alive.
Tacrolimus toxicity, chronic GVHD and outcome
Eighteen patients (34%) experienced renal toxicity while receiving tacrolimus. Two of these patients had a serum creatinine greater than 2 mg/dl at the start of tacrolimus. Four patients required hemodialysis after starting tacrolimus, with three of these patients having a serum creatinine greater than 2 mg/dl at the start of tacrolimus.
Eight patients (15%) developed new neurologic toxicity thought to be due to tacrolimus. Three patients had a seizure, two developed significant tremor, one patient experienced visual changes and one patient had psychosis within 5 days of starting tacrolimus. One patient developed visual changes after tacrolimus therapy was begun and many months later developed significant tremor. Five patients (9%) developed de novo HUS while receiving tacrolimus. Fifteen patients (28%) had tacrolimus discontinued: nine due to toxicity or presumed toxicity, two due to a flare of GVHD or lack of response, two patients had persistent HUS, and two patients had recurrent malignancy. Two patients who had tacrolimus discontinued due to presumed neurologic toxicity were subsequently found to have herpes simplex encephalitis and a cerebro-vascular accident due to aspergillus, respectively.
Seventeen of 20 evaluable patients (85%) developed chronic GVHD. Nine of 53 patients (17%) remain alive (range 640-1266 days after transplantation), with six of these being patients who had therapy changed to tacrolimus due to CSP-associated neurotoxicity. Causes of death are listed in Table 4 . Infection and GVHD were prominent causes of death.
Discussion
In our review of tacrolimus as salvage therapy for refractory acute GVHD, only two of 20 patients had any clinical improvement. The response rate of 10% and high mortality seen in these patients was not unexpected given that tacrolimus was used as tertiary therapy for resistant GVHD in most patients. Historically, the overall response rate of patients requiring secondary therapy for acute GVHD is 40% and shows an inverse correlation to the severity of GVHD at the start of treatment. 7 Only 10 to 15% of patients requiring secondary treatment will have a complete response. 7, 32 Other factors which may have adversely affected responses in these patients include early onset of GVHD and frequent HLA disparity with the donor. 7 The reported experience of tacrolimus as treatment for refractory acute GVHD is limited. In a study of six children with steroid-resistant acute GVHD, all patients showed responses in the skin and gut after tacrolimus was added, and three of four patients with liver disease responded to tacrolimus. Four of six patients died, with GVHD contributing to death in two patients. 25 A second study of 13 patients with refractory acute GVHD reported an overall response rate of 54% after conversion to tacrolimus, with two of six patients with grade III or IV GVHD showing a response. Patients who received tacrolimus within 14 days of the onset of GVHD showed a better response (86%) than those treated after that time (13%). The authors also report that all patients who received tacrolimus as first-line therapy showed a response. 26 In solid organ transplantation, where tacrolimus has been used as rescue therapy for graft rejection occurring on cyclosporine, preconversion prognostic factors associated with a favorable outcome include decreased severity of rejection [12] [13] [14] 18 and a shorter time interval between transplant and conversion to tacrolimus. 14 As the median time of conversion to tacrolimus in these patients was day 49 after transplantation, and tacrolimus was tertiary therapy in most cases, it is not known if earlier conversion would improve response. The two responders in this study had tacrolimus started on days 52 and 62 after transplantation, and tacrolimus was third-and fourth-line therapy.
It is unclear why solid organ transplant patients, who are refractory to CSP-based immunosuppression, respond after therapy is changed to tacrolimus. As calcineurin phosphatase inhibition appears to be the primary physiological effect of both CSP and tacrolimus, one would not expect to see a significant response to GVHD after conversion to tacrolimus. A study measuring the level of calcineurin phosphatase activity in marrow transplant patients receiving CSP found calcineurin activity to be lower in patients with acute GVHD when compared to those without GVHD. 33 The authors suggested that CSP-resistant GVHD was not the result of inadequate inhibition of calcineurin and questioned the benefit of treating GVHD with increased doses of CSP or conversion to tacrolimus. This raises the question of whether there are other physiologic immunosuppressive activities mediated by tacrolimus, and not seen with CSP, which contributed to the 'rescue' response seen in solid organ and hematopoietic stem cell transplants.
The etiology of CSP-associated neurotoxicities is unknown, although hypocholesterolemia, 34 hypertension, 35 hypomagnesemia, 36 concomitant high-dose glucocorticoids 37, 38 and microangiopathic hemolytic anemia 39 have been reported as clinical factors which may contribute. Neurotoxicity can occur in patients with CSP levels in the recommended target range. Tacrolimus has also been associated with neurotoxicity in marrow transplant patients, 20, 24, 40 and the incidence is similar when compared to CSP. 22, 23 Resolution of neurotoxicity is often seen after temporarily withholding or decreasing the dose of CSP, 39 but symptoms may also recur after a rechallenge with CSP. 41 It is unknown whether these patients would have tolerated rechallenge with CSP without recurrence of neurologic symptoms.
The incidence of HUS or thrombotic thrombocytopenic purpura (TTP) after marrow transplantation is estimated at 3 to 15%. [42] [43] [44] [45] The etiology of these syndromes is uncertain and has been observed after both allogeneic and autologous transplants. 42, 44, 46 Although CSP is often regarded as a precipitating event for the development of HUS or TTP, 43, 47, 48 total body irradiation 44, 49 and GVHD 43 may also be contributing factors for the development of this syndrome. Since HUS/TTP has also been seen in patients receiving tacrolimus after marrow transplant, 20, 21, 50, 51 tacrolimus may contribute to the persistence of the clinical manifestations. A single report has described conversion to tacrolimus for the management of HUS. 52 The high mortality seen in this group is indicative of the severity of HUS at the time of conversion to tacrolimus. 43 It is likely that the severity of HUS, time of onset and the presence of other coexisting transplant complications will influence treatment response and outcome.
Overall, high-risk patients with refractory acute GVHD following multiple therapies and patients with HUS who had immunosuppressive therapy changed from CSP to tacrolimus rarely responded and the mortality rate in these groups was high. Conversely, patients who had therapy changed to tacrolimus for CSP neurotoxicity often had a favorable response. It is unknown if earlier conversion to tacrolimus for refractory acute GVHD would result in improved response. The majority of patients showed good tolerance to the conversion to tacrolimus, and we conclude that conversion to tacrolimus due to CSP neurotoxicity is a reasonable alternative and can be done safely.
